Speakers
Adam Schwaid
Associate Principal Scientist
Merck & Co., Inc.
Conference Day Two: Chairing Stream A - Understanding the Molecular Mechanisms of the Inflammasome
Ali Jazayeri
Chief Scientific Officer
OMass Therapeutics
Day Two
Friday, November 6 2020
10:00 am | Discovery of Novel Gasdermin Inhibitors
Andrea Kwakowsky
Senior Research Fellow
University of Auckland
Pre-Conference Workshop Leader - Tuesday, November 16
Anil K. Goyal
CEO & Chairperson
IMMvention Therapeutix, Inc.
Day One
Thursday, November 5 2020
9:00 am | SWOT Analysis-Style Panel Discussion - Topics to be Addressed:
Ashley Mansell
Senior Director of Research & Development/Principal Investigator
Bacainn Therapeutics/Hudson Institute of Medical Research
Day 1 - Track B - Morning
11:30 am | BT032: A Novel NLRP1 & NLRP3 Inhibitor to Treat Pulmonary Inflammation
Colin R. Green
Professor/Chief Scientist
University of Auckland/OcuNexus Therapeutics, Inc. & InflammX Therapeutics, Inc.
Day Two
Friday, November 6 2020
9:30 am | Inflammasome Targeting in Ocular & Neurodegenerative Disease
David J. Bearss
CSO & President
Halia Therapeutics, Inc
Day 1 - Track B - Morning
12:00 pm | First-in-Class Allosteric Inhibitor of NEK7 to Block NLRP3 Inflammasome Assembly
Donald F. Weaver
Director
Krembil Research Institute
Day 2 - Track B - Afternoon
2:00 pm | Novel Inflammasome Targets Relevant To Alzheimer’s Disease
Elsa Sanchez- Lopez
Assistant Professor
University of California San Diego, Department of Orthopedic Surgery
Day 1 - Track A - Afternoon
2:00 pm | Mitochondria as a Central Rheostat of NLRP3 Inflammasome Activation
Gennaro Pagano
Expert Medical Director, Group Leader in Early Development
Roche
Hal Hoffman
Professor & Chief, Division of Pediatric Allergy, Immunology, Rheumatology
University of California at San Diego & Rady Children’s Hospital
Day 2 - Track B - Morning
11:30 am | Monogenic Inflammasome-Mediated Diseases
Hao Wu
Professor
Boston Children’s Hospital & Harvard Medical School
Day 1 - Track A - Morning
12:30 pm | Mechanism of Inflammasome Signaling
Humayun Sharif
Instructor
Harvard Medical School
Day 2 - Track A - Afternoon
2:30 pm | Regulation of Inflammasomes Activity: A Structural Perspective of NLRP1 Inflammasome Regulation by DPP9
James D. Thacker
Founder, Head of Discovery & Science
Therimunex Pharmaceuticals, Inc.
Day 2 - Track B - Afternoon
3:00 pm | The NLRP3 Inflammasome is a Therapeutic Target for Precision Medicine in Chronic Inflammatory Diseases: Fibrosis to Cancer
Johannes Grosse
Sr. Director Pharmacology
VIR Biotechnology
Day 2 - Track A - Morning
11:30 am | Inflammasome in Context: Crosstalk with PAMP Receptors via Purinergic Signals
Juan Pablo de Rivero Vaccari
Research Associate Professor of Neurological Surgery & The Miami Project to Cure Paralysis
University of Miami Miller School of Medicine
Day 1 - Track B - Afternoon
2:00 pm | Inflammasome Signaling After Traumatic Brain Injury: Mechanisms & Biomarkers
Karen Cashmere
Chief Commercial Officer
Zyversa Therapeutics, Inc.
Day Two
Friday, November 6 2020
9:00 am | Identifying The Optimal Therapeutic Applications for Your Inflammasome Inhibitor - Avoid InfiniteThink!
Kate Schroder
Head, Inflammasome Lab & Director IMB Centre for Inflammation & Disease Research
The University of Queensland
Day 2 - Track A - Afternoon
3:00 pm | Caspase-1 is a Therapeutic Target for Inflammatory Disease
Liang Shan
Assistant Professor
Washington University in St. Louis
Day 1 - Track A - Afternoon
2:30 pm | Targeting the CARD8 Inflammasome for HIV Treatment & Cure
Marie Kosco Vilbois
Chief Scientific Officer
AC Immune SA
Day 1 - Track A - Morning
12:00 pm | Discovering Brain Penetrant Therapeutics Targeting the NLRP3 Inflammasome Aimed to Address Unwanted Inflammatory Processes in Neurodegenerative Diseases
Martha O’Brien
Senior Research Scientist
Promega
Day One
Thursday, November 5 2020
9:30 am | Complementary Target Engagement and Functional Assays to Probe NLRP3 Pathway Antagonism
Michael Crackower
Chief Scientific Officer
Ventus Therapeutics
Day 2 - Track B - Afternoon
2:30 pm | Identification of Structurally Distinct, Potent & Selective Brain Penetrant and Peripherally Restricted NLRP3 Inhibitors
Pablo Pelegrin
Scientific Deputy Director
Biomedical Research Institute of Murcia University of Murcia
Day 1 - Track B - Afternoon
2:30 pm | Use of NLRP3 Inflammasome Activity as a Disease Biomarker for Patient Stratification & the Design of Clinical Trials Testing NLRP3 Antagonists
Paul Ashton
President & CEO
Inflammasome Therapeutics, Inc.
Day 2 - Track B - Morning
12:30 pm | Retinal Disease & Inflammasome Activation
Day One
Thursday, November 5 2020
9:00 am | SWOT Analysis-Style Panel Discussion - Topics to be Addressed:
Rebecca Coll
Lecturer in Immunobiology & Principal Investigator
Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast
Day 1 - Track A - Morning
11:30 am | Molecular Mechanisms of Inflammasome Regulation
Robert W. Keane
Professor
University of Miami Miller School of Medicine
Day 1 - Track B - Morning
12:30 pm | Systemic Inflammatory Complications Following Traumatic Brain Injury
Rugmani Iyer
Senior Scientist
Merck & Co., Inc.
Day 2 - Track A - Afternoon
2:00 pm | Exploring Inflammasome Activation & Upstream Signalling to Identify Drug Targets
Seung-Yong Seong
Professor, Department of Microbiology & Immunology & Co- CEO
Shaperon Inc.
Day 2 - Track B - Morning
12:00 pm | Randomized Double-Blind, Placebo- Controlled Phase 2 Trial of NuGel, an Inflammasome Inhibitor, for Atopic Dermatitis
Steve Glover
Co-Founder, Chief Executive Officer & Chairman
Zyversa Therapeutics, Inc.
Day One
Thursday, November 5 2020
9:00 am | SWOT Analysis-Style Panel Discussion - Topics to be Addressed:
Sunhwa Kim
Principal Scientist
Merck Research Institute
Day 2 - Track A - Morning
12:30 pm | Investigating Intricacies of Inflammasome Crosstalk with Other Systems
Vishal Singh
Assistant Professor
Pennsylvania State University